aldosterone has been researched along with 2019 Novel Coronavirus Disease in 42 studies
| Excerpt | Relevance | Reference |
|---|---|---|
| " The former dosage of ACEis/ARBs was continued in one group while in another group, the ACEis/ARBs were replaced by amlodipine ± carvedilol according to the dose equivalents." | 3.01 | Effects of Renin-Angiotensin-Aldosterone Inhibitors on Early Outcomes of Hypertensive COVID-19 Patients: A Randomized Triple-Blind Clinical Trial. ( Ashraf, H; Bahreini, M; Ghoghaei, M; Najmeddin, F; Rasooli, F; Salehi, M; Soleimani, A; Solhjoo, M, 2021) |
| "Aldosterone is a key component of Renin-Angiotensin-Aldosterone System (RAAS)." | 1.91 | Evaluation of Possible Association between Serum Levels of Aldosterone and Cortisol with Clinical Symptoms Progression in COVID-19 Suspicious Outpatients Tested for SARS-CoV2 RT-PCR: An Analytical Cross-Sectional Study. ( Adelipour, M; Golabi, S; Maghsoudi, F; Mobarak, S; Naghashpour, M; Piri, M; Seyedtabib, M, 2023) |
| "Stroke is a severe and frequent complication of Fabry disease (FD), affecting both males and females." | 1.56 | Fabry disease patients have an increased risk of stroke in the COVID-19 ERA. A hypothesis. ( Bonardo, P; Reisin, RC; Rozenfeld, P, 2020) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 42 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Campana, P | 2 |
| Palaia, ME | 1 |
| Conte, M | 1 |
| Cante, T | 1 |
| Petraglia, L | 1 |
| Femminella, GD | 2 |
| Parisi, V | 1 |
| Leosco, D | 1 |
| Faour, WH | 1 |
| Choaib, A | 1 |
| Issa, E | 1 |
| Choueiry, FE | 1 |
| Shbaklo, K | 1 |
| Alhajj, M | 1 |
| Sawaya, RT | 1 |
| Harhous, Z | 1 |
| Alefishat, E | 1 |
| Nader, M | 1 |
| Sen, R | 1 |
| Sengupta, D | 1 |
| Mukherjee, A | 1 |
| Akin, S | 1 |
| Schriek, P | 1 |
| van Nieuwkoop, C | 1 |
| Neuman, RI | 1 |
| Meynaar, I | 1 |
| van Helden, EJ | 1 |
| Bouazzaoui, HE | 1 |
| Baak, R | 1 |
| Veuger, M | 1 |
| Mairuhu, RATA | 1 |
| van den Berg, L | 1 |
| van Driel, V | 1 |
| Visser, LE | 1 |
| de Jonge, E | 1 |
| Garrelds, IM | 1 |
| Duynstee, JFAB | 1 |
| van Rooden, JK | 1 |
| Ludikhuize, J | 1 |
| Verdonk, K | 1 |
| Caliskan, K | 1 |
| Jansen, T | 1 |
| van Schaik, RHN | 1 |
| Danser, AHJ | 1 |
| Sharma, A | 1 |
| Elharram, M | 1 |
| Afilalo, J | 1 |
| Flannery, A | 1 |
| Afilalo, M | 1 |
| Tselios, C | 1 |
| Ni, J | 1 |
| Ezekowitz, JA | 1 |
| Cheng, MP | 1 |
| Ambrosy, AP | 1 |
| Zannad, F | 1 |
| Brophy, JM | 1 |
| Giannetti, N | 1 |
| Bessissow, A | 1 |
| Kronfli, N | 1 |
| Marelli, A | 1 |
| Aziz, H | 1 |
| Alqahtani, M | 1 |
| Aflaki, M | 1 |
| Craig, M | 1 |
| Lopes, RD | 1 |
| Ferreira, JP | 1 |
| Salem, JE | 1 |
| Hammoudi, N | 1 |
| Pinna, B | 1 |
| Ederhy, S | 1 |
| Lamazière, A | 1 |
| Fenioux, C | 1 |
| Redheuil, A | 1 |
| Salem, P | 1 |
| Ribet, C | 1 |
| Hamwy, O | 1 |
| Marcelin, AG | 1 |
| Burrel, S | 1 |
| Funck-Brentano, C | 1 |
| Montalescot, G | 1 |
| Lacorte, JM | 1 |
| Gandjbakhch, E | 1 |
| Benveniste, O | 1 |
| Saadoun, D | 1 |
| Allenbach, Y | 1 |
| Boussouar, S | 1 |
| Prifti, E | 1 |
| Cacoub, P | 1 |
| Cannavo, A | 1 |
| Liccardo, D | 1 |
| Gelzo, M | 1 |
| Amato, F | 1 |
| Gentile, I | 1 |
| Pinchera, B | 1 |
| Parrella, R | 1 |
| DE Rosa, A | 1 |
| Gambino, G | 1 |
| Marzano, F | 1 |
| Ferrara, N | 1 |
| Paolocci, N | 1 |
| Rengo, G | 1 |
| Castaldo, G | 1 |
| Weber, T | 1 |
| Amar, J | 1 |
| de Backer, T | 1 |
| Burkard, T | 1 |
| van der Giet, M | 1 |
| Gosse, P | 1 |
| Januszewicz, A | 1 |
| Kahan, T | 1 |
| Mancia, G | 1 |
| Mayer, CC | 1 |
| Muiesan, ML | 1 |
| Stergiou, GS | 1 |
| Tsioufis, K | 1 |
| Vaisse, B | 1 |
| Kreutz, R | 1 |
| Loader, J | 1 |
| Taylor, FC | 1 |
| Lampa, E | 1 |
| Sundström, J | 2 |
| Kovacs, J | 1 |
| Talib, S | 1 |
| Khashan, A | 1 |
| Garsondiya, B | 1 |
| Carson, MP | 1 |
| Sezer, S | 1 |
| Bal, C | 1 |
| Kalem, AK | 1 |
| Kayaaslan, B | 1 |
| Eser, F | 1 |
| Hasanoglu, İ | 1 |
| Akıncı, E | 1 |
| Güner, R | 1 |
| Erel, Ö | 1 |
| Yılmaz, G | 1 |
| Keikha, M | 1 |
| Karbalaei, M | 1 |
| Papadopoulos, KI | 1 |
| Papadopoulou, A | 1 |
| Aw, TC | 1 |
| Tardif, JC | 1 |
| Rouleau, J | 1 |
| Chertow, GM | 1 |
| Al-Shurbaji, A | 1 |
| Lisovskaja, V | 1 |
| Gustavson, S | 1 |
| Zhao, Y | 1 |
| Bouabdallaoui, N | 1 |
| Desai, AS | 1 |
| Chernyavskiy, A | 1 |
| Evsina, M | 1 |
| Merkely, B | 1 |
| McMurray, JJV | 1 |
| Pfeffer, MA | 1 |
| Wadhwa, B | 1 |
| Malhotra, V | 1 |
| Kerai, S | 1 |
| Husain, F | 1 |
| Pandey, NB | 1 |
| Saxena, KN | 1 |
| Singh, V | 1 |
| Quinn, TM | 1 |
| Li, F | 1 |
| Gaughan, E | 1 |
| Shankar-Hari, M | 1 |
| Mills, B | 1 |
| Antonelli, J | 1 |
| Bruce, A | 1 |
| Finlayson, K | 1 |
| Moore, A | 1 |
| Dhaliwal, K | 1 |
| Edwards, C | 1 |
| Naghashpour, M | 1 |
| Adelipour, M | 1 |
| Mobarak, S | 1 |
| Piri, M | 1 |
| Seyedtabib, M | 1 |
| Maghsoudi, F | 1 |
| Golabi, S | 1 |
| Bornstein, SR | 1 |
| Dalan, R | 1 |
| Hopkins, D | 1 |
| Mingrone, G | 1 |
| Boehm, BO | 1 |
| Henry, BM | 1 |
| Vikse, J | 1 |
| Benoit, S | 1 |
| Favaloro, EJ | 1 |
| Lippi, G | 1 |
| Alexandre, J | 1 |
| Cracowski, JL | 1 |
| Richard, V | 1 |
| Bouhanick, B | 1 |
| Mareev, YV | 1 |
| Mareev, VY | 1 |
| Pechère-Bertschi, A | 1 |
| Ponte, B | 1 |
| Wuerzner, G | 1 |
| Curfman, G | 1 |
| Dudoignon, E | 1 |
| Moreno, N | 1 |
| Deniau, B | 1 |
| Coutrot, M | 1 |
| Longer, R | 1 |
| Amiot, Q | 1 |
| Mebazaa, A | 1 |
| Pirracchio, R | 1 |
| Depret, F | 1 |
| Legrand, M | 1 |
| Culebras, E | 1 |
| Hernández, F | 1 |
| Flocco, V | 1 |
| Aruta, F | 1 |
| Cacciatore, F | 1 |
| Abete, P | 1 |
| Sunavala-Dossabhoy, G | 1 |
| Ostermann, M | 1 |
| Lumlertgul, N | 1 |
| Forni, LG | 1 |
| Hoste, E | 1 |
| Gormez, S | 1 |
| Ekicibasi, E | 1 |
| Degirmencioglu, A | 1 |
| Paudel, A | 1 |
| Erdim, R | 1 |
| Gumusel, HK | 1 |
| Eroglu, E | 1 |
| Tanboga, IH | 1 |
| Dagdelen, S | 1 |
| Sariguzel, N | 1 |
| Kirisoglu, CE | 1 |
| Pamukcu, B | 1 |
| Otto, CM | 1 |
| Young, MJ | 1 |
| Clyne, CD | 1 |
| Chapman, KE | 1 |
| Rieder, M | 1 |
| Wirth, L | 1 |
| Pollmeier, L | 1 |
| Jeserich, M | 1 |
| Goller, I | 1 |
| Baldus, N | 1 |
| Schmid, B | 1 |
| Busch, HJ | 1 |
| Hofmann, M | 1 |
| Kern, W | 1 |
| Bode, C | 1 |
| Duerschmied, D | 1 |
| Lother, A | 1 |
| Mabillard, H | 2 |
| Sayer, JA | 2 |
| Rojas, M | 1 |
| Acosta-Ampudia, Y | 1 |
| Monsalve, DM | 1 |
| Ramírez-Santana, C | 1 |
| Anaya, JM | 1 |
| Savarese, G | 1 |
| Benson, L | 1 |
| Lund, LH | 1 |
| Reisin, RC | 1 |
| Rozenfeld, P | 1 |
| Bonardo, P | 1 |
| Tomasoni, D | 1 |
| Petrie, MC | 1 |
| Adamo, M | 1 |
| Metra, M | 1 |
| Barone Gibbs, B | 1 |
| Conroy, MB | 1 |
| Huber, K | 1 |
| Muldoon, MF | 1 |
| Perera, S | 1 |
| Jakicic, JM | 1 |
| Pawlikowski, M | 1 |
| Winczyk, K | 1 |
| Aparisi, Á | 1 |
| Catalá, P | 1 |
| Amat-Santos, IJ | 1 |
| Marcos-Mangas, M | 1 |
| López-Otero, D | 1 |
| Veras, C | 1 |
| López-Pais, J | 1 |
| Cabezón-Villalba, G | 1 |
| Cacho Antonio, CE | 1 |
| Candela, J | 1 |
| Antúnez-Muiños, P | 1 |
| Gil, JF | 1 |
| González Ferrero, T | 1 |
| Rojas, G | 1 |
| Pérez-Poza, M | 1 |
| Uribarri, A | 1 |
| Otero-García, O | 1 |
| García-Granja, PE | 1 |
| Jiménez Ramos, V | 1 |
| Revilla, A | 1 |
| Dueñas, C | 1 |
| Gómez, I | 1 |
| González-Juanatey, JR | 1 |
| San Román, JA | 1 |
| Palazzuoli, A | 1 |
| Tecson, KM | 1 |
| McCullough, PA | 1 |
| Najmeddin, F | 1 |
| Solhjoo, M | 1 |
| Ashraf, H | 1 |
| Salehi, M | 1 |
| Rasooli, F | 1 |
| Ghoghaei, M | 1 |
| Soleimani, A | 1 |
| Bahreini, M | 1 |
| Shibata, S | 1 |
| Kishi, T | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Management of Renin-Angiotensin-Aldosterone System Blockade in Patients Admitted in Hospital With Confirmed Coronavirus Disease (COVID-19) Infection: The McGill RAAS-COVID-19 Randomized Controlled Trial[NCT04508985] | 46 participants (Actual) | Interventional | 2020-10-01 | Completed | |||
| A Study of a 10-days Fenofibrate Treatment, or Until Discharge From Hospital, Among COVID-19 Infected Patients Requiring Hospitalization[NCT04661930] | Phase 3 | 55 participants (Anticipated) | Interventional | 2021-01-01 | Recruiting | ||
| Time of Recovery and Prognostic Factors of COVID-19 Pneumonia[NCT04324684] | 198 participants (Actual) | Observational | 2020-03-31 | Completed | |||
| FEnofibRate as a Metabolic INtervention for Coronavirus Disease 2019[NCT04517396] | Phase 2 | 701 participants (Actual) | Interventional | 2020-08-18 | Completed | ||
| Counter-Regulatory Hormonal and Stress Systems in Patients With COVID-19[NCT05736900] | 200 participants (Actual) | Interventional | 2020-09-10 | Completed | |||
| Laparoscopic Bariatric Surgery During Phase 2-3 Covid-19 Pandemic in Italy: a Multicenter, Prospective, Observational Study.[NCT04480034] | 1,600 participants (Anticipated) | Observational | 2020-07-15 | Recruiting | |||
| Acute Kidney Injury in COVID-19 Patients Admitted to the ICU: a Multicenter Cohort Analysis in 9 Large Hospitals in Belgium[NCT04997915] | 1,286 participants (Actual) | Observational | 2020-02-01 | Completed | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Death from any cause during the observation period (NCT04517396)
Timeframe: Up to 30 days
| Intervention | Participants (Count of Participants) |
|---|---|
| Fenofibrate + Usual Care | 19 |
| Placebo + Usual Care | 22 |
The exploratory global rank score, or global severity score, is a nonparametric, hierarchically ranked outcome. The global rank score was generated by ranking all 701 participants on a scale of 1 to 701, from worst to best clinical outcomes. Participants were ranked by (1) time to death; (2) the number of days supported by invasive mechanical ventilation or extracorporeal membrane oxygenation (ECMO); (3) The inspired concentration of oxygen/percent oxygen saturation (FiO2/SpO2) ratio area under the curve; (4) The number of days out of the hospital during the 30 day-period following randomization. (NCT04517396)
Timeframe: Up to 30 days
| Intervention | score on a scale (Median) |
|---|---|
| Fenofibrate + Usual Care | 5.03 |
| Placebo + Usual Care | 5.03 |
Number of days that participants were alive and out of the hospital during the 30 days following randomization (NCT04517396)
Timeframe: Up to 30 days
| Intervention | days (Median) |
|---|---|
| Fenofibrate + Usual Care | 30 |
| Placebo + Usual Care | 30 |
Number of days participants were alive, out of the intensive care unit, free of mechanical ventilation/extracorporeal membrane oxygenation, or maximal available respiratory support during the 30 days that followed randomization (NCT04517396)
Timeframe: Up to 30 days
| Intervention | days (Mean) |
|---|---|
| Fenofibrate + Usual Care | 28.8 |
| Placebo + Usual Care | 28.3 |
The primary endpoint of the trial is a global rank score that ranks patient outcomes according to 5 factors. The global rank score, or global severity score, is a nonparametric, hierarchically ranked outcome. The global rank score was generated by ranking all 701 participants on a scale of 1 to 701, from worst to best clinical outcomes. Participants were ranked by (1) time to death; (2) the number of days supported by invasive mechanical ventilation or extracorporeal membrane oxygenation (ECMO); (3) The inspired concentration of oxygen/percent oxygen saturation (FiO2/SpO2) ratio area under the curve; (4) For participants enrolled as outpatients who are subsequently hospitalized, the number of days out of the hospital during the 30 day-period following randomization; (5) For participants enrolled as outpatients who don't get hospitalized during the 30-day observation period, the modified Borg dyspnea scale (NCT04517396)
Timeframe: 30 days
| Intervention | Ranked Severity Score (Median) |
|---|---|
| Fenofibrate + Usual Care | 5.32 |
| Placebo + Usual Care | 5.33 |
The secondary global rank score, or global severity score, is a nonparametric, hierarchically ranked outcome. The global rank score was generated by ranking all 701 participants on a scale of 1 to 701, from worst to best clinical outcomes. Participants were ranked by (1) time to death; (2) the number of days supported by invasive mechanical ventilation or extracorporeal membrane oxygenation (ECMO); (3) The inspired concentration of oxygen/percent oxygen saturation (FiO2/SpO2) ratio area under the curve; (4) For participants enrolled as outpatients who are subsequently hospitalized, the number of days out of the hospital during the 30 day-period following randomization; (5) For participants enrolled as outpatients who don't get hospitalized during the 30-day observation period, a COVID-19 symptom scale rating fever, cough, dyspnea, muscle aches, sore throat, loss of smell or taste, headache, diarrhea, fatigue, nausea/vomiting, chest pain (each are rated from 0-10 then summed). (NCT04517396)
Timeframe: Up to 30 days
| Intervention | score on a scale (Median) |
|---|---|
| Fenofibrate + Usual Care | 5.05 |
| Placebo + Usual Care | 5.05 |
A seven-category ordinal scale consisting of the following categories: 1, not hospitalized with resumption of normal activities; 2, not hospitalized, but unable to resume normal activities; 3, hospitalized, not requiring supplemental oxygen; 4, hospitalized, requiring supplemental oxygen; 5, hospitalized, requiring nasal high-flow oxygen therapy, noninvasive mechanical ventilation, or both; 6, hospitalized, requiring extracorporeal membrane oxygenation (ECMO), invasive mechanical ventilation, or both; and 7, death. (NCT04517396)
Timeframe: At 15 days
| Intervention | score on a scale (Median) |
|---|---|
| Fenofibrate + Usual Care | 1 |
| Placebo + Usual Care | 1 |
12 reviews available for aldosterone and 2019 Novel Coronavirus Disease
| Article | Year |
|---|---|
Mechanisms of COVID-19-induced kidney injury and current pharmacotherapies.
Topics: Acute Kidney Injury; Aldosterone; Angiotensins; Antibodies, Monoclonal, Humanized; Autopsy; Biopsy; | 2022 |
Mechanical dependency of the SARS-CoV-2 virus and the renin-angiotensin-aldosterone (RAAS) axis: a possible new threat.
Topics: Aldosterone; Angiotensins; COVID-19; Humans; Hypertension; Peptidyl-Dipeptidase A; Renin; Renin-Angi | 2022 |
Renin-Angiotensin Aldosterone System Inhibitors and COVID-19: A Systematic Review and Meta-Analysis Revealing Critical Bias Across a Body of Observational Research.
Topics: Aldosterone; Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Angiotensin Receptor Antagonis | 2022 |
Global distribution of ACE1 (rs4646994) and ACE2 (rs2285666) polymorphisms associated with COVID-19: A systematic review and meta-analysis.
Topics: Aldosterone; Angiotensin-Converting Enzyme 2; Angiotensins; COVID-19; Humans; Peptidyl-Dipeptidase A | 2022 |
A protective erythropoietin evolutionary landscape, NLRP3 inflammasome regulation, and multisystem inflammatory syndrome in children.
Topics: Aldosterone; Angiotensin II; Child; COVID-19; Endothelial Cells; Erythropoietin; Humans; Inflammasom | 2023 |
Hyperinflammation and derangement of renin-angiotensin-aldosterone system in COVID-19: A novel hypothesis for clinically suspected hypercoagulopathy and microvascular immunothrombosis.
Topics: Aldosterone; Betacoronavirus; Coronavirus Infections; COVID-19; Humans; Immunity, Innate; Inflammati | 2020 |
Renin-angiotensin-aldosterone system and COVID-19 infection.
Topics: Aldosterone; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme 2; Angiotensin-C | 2020 |
What every Intensivist should know about COVID-19 associated acute kidney injury.
Topics: Acute Kidney Injury; Aldosterone; Anticoagulants; COVID-19; Critical Care; Critical Illness; Humans; | 2020 |
Endocrine aspects of ACE2 regulation: RAAS, steroid hormones and SARS-CoV-2.
Topics: Aldosterone; Angiotensin-Converting Enzyme 2; Angiotensin-Converting Enzyme Inhibitors; Animals; Bet | 2020 |
Electrolyte Disturbances in SARS-CoV-2 Infection.
Topics: Aldosterone; Betacoronavirus; Coronavirus Infections; COVID-19; Electrolytes; Humans; Hypokalemia; P | 2020 |
Electrolyte Disturbances in SARS-CoV-2 Infection.
Topics: Aldosterone; Betacoronavirus; Coronavirus Infections; COVID-19; Electrolytes; Humans; Hypokalemia; P | 2020 |
Electrolyte Disturbances in SARS-CoV-2 Infection.
Topics: Aldosterone; Betacoronavirus; Coronavirus Infections; COVID-19; Electrolytes; Humans; Hypokalemia; P | 2020 |
Electrolyte Disturbances in SARS-CoV-2 Infection.
Topics: Aldosterone; Betacoronavirus; Coronavirus Infections; COVID-19; Electrolytes; Humans; Hypokalemia; P | 2020 |
Endocrine and metabolic aspects of COVID-19.
Topics: Aging; Aldosterone; Angiotensin II; Angiotensin-Converting Enzyme 2; COVID-19; Diabetes Mellitus; Hu | 2021 |
Chronic use of renin-angiotensin-aldosterone inhibitors in hypertensive COVID-19 patients: Results from a Spanish registry and meta-analysis.
Topics: Aldosterone; Angiotensin Receptor Antagonists; Angiotensins; Antihypertensive Agents; COVID-19; Huma | 2022 |
5 trials available for aldosterone and 2019 Novel Coronavirus Disease
| Article | Year |
|---|---|
A randomized controlled trial of renin-angiotensin-aldosterone system inhibitor management in patients admitted in hospital with COVID-19.
Topics: Adult; Aged; Aldosterone; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors | 2022 |
Potassium reduction with sodium zirconium cyclosilicate in patients with heart failure.
Topics: Aldosterone; COVID-19; Heart Failure; Humans; Pandemics; Potassium; Stroke Volume | 2023 |
Phase 2 randomised placebo-controlled trial of spironolactone and dexamethasone versus dexamethasone in COVID-19 hospitalised patients in Delhi.
Topics: Aldosterone; Angiotensin II; COVID-19; COVID-19 Drug Treatment; Dexamethasone; Humans; Randomized Co | 2023 |
Effect of Reducing Sedentary Behavior on Blood Pressure (RESET BP): Rationale, design, and methods.
Topics: Accelerometry; Adult; Aged; Aldosterone; Blood Pressure; Blood Pressure Monitoring, Ambulatory; COVI | 2021 |
Effects of Renin-Angiotensin-Aldosterone Inhibitors on Early Outcomes of Hypertensive COVID-19 Patients: A Randomized Triple-Blind Clinical Trial.
Topics: Aldosterone; Amlodipine; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; | 2021 |
25 other studies available for aldosterone and 2019 Novel Coronavirus Disease
| Article | Year |
|---|---|
The elderly at risk: aldosterone as modulator of the immune response to SARS-CoV-2 infection.
Topics: Adaptive Immunity; Aged; Aldosterone; COVID-19; Humans; Renin-Angiotensin System; SARS-CoV-2 | 2022 |
A low aldosterone/renin ratio and high soluble ACE2 associate with COVID-19 severity.
Topics: Aldosterone; Angiotensin-Converting Enzyme 2; COVID-19; Humans; Renin; Renin-Angiotensin System; SAR | 2022 |
Echocardiography and renin-aldosterone interplay as predictors of death in COVID-19.
Topics: Aldosterone; Biomarkers; COVID-19; Echocardiography; Humans; Renin-Angiotensin System; SARS-CoV-2 | 2022 |
Serum galectin-3 and aldosterone: potential biomarkers of cardiac complications in patients with COVID-19.
Topics: Actins; Aldosterone; Biomarkers; COVID-19; Fibrosis; Galectin 3; Humans; SARS-CoV-2; Troponin I | 2022 |
Covid-19 associated reduction in hypertension-related diagnostic and therapeutic procedures in Excellence Centers of the European Society of Hypertension.
Topics: Aldosterone; Antihypertensive Agents; Blood Pressure; Blood Pressure Monitoring, Ambulatory; Catecho | 2022 |
A 77-Year-Old Man with Heparin-Induced Aldosterone Suppression Causing Hyperkalemia.
Topics: Aged; Aldosterone; Anticoagulants; COVID-19; Heparin; Humans; Hyperkalemia; Male; Potassium | 2022 |
COVID-19 patients with altered steroid hormone levels are more likely to have higher disease severity.
Topics: 17-alpha-Hydroxypregnenolone; 17-alpha-Hydroxyprogesterone; Aldosterone; Androstenedione; Androstero | 2022 |
Evaluation of Possible Association between Serum Levels of Aldosterone and Cortisol with Clinical Symptoms Progression in COVID-19 Suspicious Outpatients Tested for SARS-CoV2 RT-PCR: An Analytical Cross-Sectional Study.
Topics: Aldosterone; COVID-19; COVID-19 Testing; Cross-Sectional Studies; Female; Humans; Hydrocortisone; Ma | 2023 |
Endocrine and metabolic link to coronavirus infection.
Topics: Aldosterone; Betacoronavirus; Comorbidity; Coronavirus Infections; COVID-19; Diabetes Mellitus, Type | 2020 |
Endocrine and metabolic link to coronavirus infection.
Topics: Aldosterone; Betacoronavirus; Comorbidity; Coronavirus Infections; COVID-19; Diabetes Mellitus, Type | 2020 |
Endocrine and metabolic link to coronavirus infection.
Topics: Aldosterone; Betacoronavirus; Comorbidity; Coronavirus Infections; COVID-19; Diabetes Mellitus, Type | 2020 |
Endocrine and metabolic link to coronavirus infection.
Topics: Aldosterone; Betacoronavirus; Comorbidity; Coronavirus Infections; COVID-19; Diabetes Mellitus, Type | 2020 |
Endocrine and metabolic link to coronavirus infection.
Topics: Aldosterone; Betacoronavirus; Comorbidity; Coronavirus Infections; COVID-19; Diabetes Mellitus, Type | 2020 |
Endocrine and metabolic link to coronavirus infection.
Topics: Aldosterone; Betacoronavirus; Comorbidity; Coronavirus Infections; COVID-19; Diabetes Mellitus, Type | 2020 |
Endocrine and metabolic link to coronavirus infection.
Topics: Aldosterone; Betacoronavirus; Comorbidity; Coronavirus Infections; COVID-19; Diabetes Mellitus, Type | 2020 |
Endocrine and metabolic link to coronavirus infection.
Topics: Aldosterone; Betacoronavirus; Comorbidity; Coronavirus Infections; COVID-19; Diabetes Mellitus, Type | 2020 |
Endocrine and metabolic link to coronavirus infection.
Topics: Aldosterone; Betacoronavirus; Comorbidity; Coronavirus Infections; COVID-19; Diabetes Mellitus, Type | 2020 |
Endocrine and metabolic link to coronavirus infection.
Topics: Aldosterone; Betacoronavirus; Comorbidity; Coronavirus Infections; COVID-19; Diabetes Mellitus, Type | 2020 |
Endocrine and metabolic link to coronavirus infection.
Topics: Aldosterone; Betacoronavirus; Comorbidity; Coronavirus Infections; COVID-19; Diabetes Mellitus, Type | 2020 |
Endocrine and metabolic link to coronavirus infection.
Topics: Aldosterone; Betacoronavirus; Comorbidity; Coronavirus Infections; COVID-19; Diabetes Mellitus, Type | 2020 |
Endocrine and metabolic link to coronavirus infection.
Topics: Aldosterone; Betacoronavirus; Comorbidity; Coronavirus Infections; COVID-19; Diabetes Mellitus, Type | 2020 |
Endocrine and metabolic link to coronavirus infection.
Topics: Aldosterone; Betacoronavirus; Comorbidity; Coronavirus Infections; COVID-19; Diabetes Mellitus, Type | 2020 |
Endocrine and metabolic link to coronavirus infection.
Topics: Aldosterone; Betacoronavirus; Comorbidity; Coronavirus Infections; COVID-19; Diabetes Mellitus, Type | 2020 |
Endocrine and metabolic link to coronavirus infection.
Topics: Aldosterone; Betacoronavirus; Comorbidity; Coronavirus Infections; COVID-19; Diabetes Mellitus, Type | 2020 |
Endocrine and metabolic link to coronavirus infection.
Topics: Aldosterone; Betacoronavirus; Comorbidity; Coronavirus Infections; COVID-19; Diabetes Mellitus, Type | 2020 |
Endocrine and metabolic link to coronavirus infection.
Topics: Aldosterone; Betacoronavirus; Comorbidity; Coronavirus Infections; COVID-19; Diabetes Mellitus, Type | 2020 |
Endocrine and metabolic link to coronavirus infection.
Topics: Aldosterone; Betacoronavirus; Comorbidity; Coronavirus Infections; COVID-19; Diabetes Mellitus, Type | 2020 |
Endocrine and metabolic link to coronavirus infection.
Topics: Aldosterone; Betacoronavirus; Comorbidity; Coronavirus Infections; COVID-19; Diabetes Mellitus, Type | 2020 |
Endocrine and metabolic link to coronavirus infection.
Topics: Aldosterone; Betacoronavirus; Comorbidity; Coronavirus Infections; COVID-19; Diabetes Mellitus, Type | 2020 |
Endocrine and metabolic link to coronavirus infection.
Topics: Aldosterone; Betacoronavirus; Comorbidity; Coronavirus Infections; COVID-19; Diabetes Mellitus, Type | 2020 |
Endocrine and metabolic link to coronavirus infection.
Topics: Aldosterone; Betacoronavirus; Comorbidity; Coronavirus Infections; COVID-19; Diabetes Mellitus, Type | 2020 |
Endocrine and metabolic link to coronavirus infection.
Topics: Aldosterone; Betacoronavirus; Comorbidity; Coronavirus Infections; COVID-19; Diabetes Mellitus, Type | 2020 |
Endocrine and metabolic link to coronavirus infection.
Topics: Aldosterone; Betacoronavirus; Comorbidity; Coronavirus Infections; COVID-19; Diabetes Mellitus, Type | 2020 |
[Role of age, comorbidity and renin- angiotensin-aldosterone system in COVID-19. Effects of ACE inhibitors and angiotensin receptor blockers].
Topics: Aldosterone; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Angiotensin | 2020 |
[Renin-angiotensin-aldosterone blockers and Covic-19 infection : friends or enemies ?]
Topics: Aldosterone; Angiotensin-Converting Enzyme 2; Angiotensin-Converting Enzyme Inhibitors; Angiotensins | 2020 |
Renin-Angiotensin-Aldosterone Inhibitors and Susceptibility to and Severity of COVID-19.
Topics: Aldosterone; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Angiotensin | 2020 |
Activation of the renin-angiotensin-aldosterone system is associated with Acute Kidney Injury in COVID-19.
Topics: Acute Kidney Injury; Aged; Aldosterone; Betacoronavirus; Coronavirus Infections; COVID-19; Creatinin | 2020 |
ACE2 is on the X chromosome: could this explain COVID-19 gender differences?
Topics: Aldosterone; Angiotensins; Betacoronavirus; Coronavirus Infections; COVID-19; Female; Heart Failure; | 2020 |
Can aldosterone increase interleukin-6 levels in Covid-19 pneumonia?
Topics: Aldosterone; COVID-19; Cytokine Release Syndrome; Female; Guillain-Barre Syndrome; Humans; Interleuk | 2021 |
Renin-angiotensin II-aldosterone axis in SARS-CoV-2-associated xerostomia.
Topics: Aldosterone; Angiotensin II; COVID-19; Humans; Renin; SARS-CoV-2; Xerostomia | 2022 |
Association between renin-angiotensin-aldosterone system inhibitor treatment, neutrophil-lymphocyte ratio, D-Dimer and clinical severity of COVID-19 in hospitalized patients: a multicenter, observational study.
Topics: Adult; Aged; Aldosterone; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors | 2021 |
Heartbeat: interaction of renin-angiotensin-aldosterone blocking drugs with COVID-19 disease susceptibility and severity.
Topics: Aldosterone; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Angiotensin | 2020 |
Serum ACE2, Angiotensin II, and Aldosterone Levels Are Unchanged in Patients With COVID-19.
Topics: Aldosterone; Angiotensin II; Angiotensin-Converting Enzyme 2; Angiotensin-Converting Enzyme Inhibito | 2021 |
How Important Is the Assessment of Soluble ACE-2 in COVID-19?
Topics: Aldosterone; Angiotensin II; Angiotensin-Converting Enzyme 2; COVID-19; Humans; SARS-CoV-2 | 2021 |
Association between renin-angiotensin-aldosterone system inhibitor use and COVID-19 hospitalization and death: a 1.4 million patient nationwide registry analysis.
Topics: Aldosterone; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; COVID-19; H | 2021 |
Fabry disease patients have an increased risk of stroke in the COVID-19 ERA. A hypothesis.
Topics: Aldosterone; Angiotensin-Converting Enzyme 2; COVID-19; Endothelium, Vascular; Fabry Disease; Female | 2020 |
Renin-angiotensin-aldosterone inhibitors and COVID-19: nearing the end of a media-fuelled controversy.
Topics: Aldosterone; Angiotensin Receptor Antagonists; Angiotensins; COVID-19; Heart Failure; Hospitalizatio | 2021 |
Impact of renin-angiotensin-aldosterone system inhibitor continuation on outcomes for patients with severe coronavirus disease 2019 manifestations.
Topics: Aldosterone; Angiotensin-Converting Enzyme Inhibitors; COVID-19; Humans; Renin-Angiotensin System; S | 2021 |
Updates on Renin-Angiotensin System Blockers in Hypertensive Patients With COVID-19.
Topics: Aldosterone; Angiotensins; Antihypertensive Agents; COVID-19; Humans; Hypertension; Renin; Renin-Ang | 2021 |